Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions

Autores
Ridruejo, Ezequiel; Pereson, Matías Javier; Flichman, Diego Martin; Di Lello, Federico Alejandro
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Pereson, Matías Javier. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Flichman, Diego Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Di Lello, Federico Alejandro. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
DIRECT-ACTING ANTIVIRAL
HEPATITIS C VIRUS
RESISTANCE
TREATMENT FAILURE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/170891
Acceder
id CONICETDig_02b7f8703bee0d39164b34763cb53f50
oai_identifier_str oai:ri.conicet.gov.ar:11336/170891
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutionsRidruejo, EzequielPereson, Matías JavierFlichman, Diego MartinDi Lello, Federico AlejandroDIRECT-ACTING ANTIVIRALHEPATITIS C VIRUSRESISTANCETREATMENT FAILUREhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Pereson, Matías Javier. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; ArgentinaFil: Flichman, Diego Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; ArgentinaFil: Di Lello, Federico Alejandro. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaBaishideng Publishing Group2021-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/170891Ridruejo, Ezequiel; Pereson, Matías Javier; Flichman, Diego Martin; Di Lello, Federico Alejandro; Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions; Baishideng Publishing Group; World Journal of Hepatology; 13; 9; 9-2021; 1069-10781948-5182CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v13.i9.1069info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:10:54Zoai:ri.conicet.gov.ar:11336/170891instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:10:55.112CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
title Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
spellingShingle Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
Ridruejo, Ezequiel
DIRECT-ACTING ANTIVIRAL
HEPATITIS C VIRUS
RESISTANCE
TREATMENT FAILURE
title_short Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
title_full Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
title_fullStr Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
title_full_unstemmed Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
title_sort Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
dc.creator.none.fl_str_mv Ridruejo, Ezequiel
Pereson, Matías Javier
Flichman, Diego Martin
Di Lello, Federico Alejandro
author Ridruejo, Ezequiel
author_facet Ridruejo, Ezequiel
Pereson, Matías Javier
Flichman, Diego Martin
Di Lello, Federico Alejandro
author_role author
author2 Pereson, Matías Javier
Flichman, Diego Martin
Di Lello, Federico Alejandro
author2_role author
author
author
dc.subject.none.fl_str_mv DIRECT-ACTING ANTIVIRAL
HEPATITIS C VIRUS
RESISTANCE
TREATMENT FAILURE
topic DIRECT-ACTING ANTIVIRAL
HEPATITIS C VIRUS
RESISTANCE
TREATMENT FAILURE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.
Fil: Ridruejo, Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Pereson, Matías Javier. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina
Fil: Flichman, Diego Martin. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas en Retrovirus y Sida. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas en Retrovirus y Sida; Argentina
Fil: Di Lello, Federico Alejandro. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Instituto de Investigaciones en Bacteriología y Virología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions (RAS). However, the consequence of resistance selection during new direct-acting antiviral drug (DAA) treatment is not necessarily the therapeutic failure. In fact, DAA treatment has shown a high rate (> 95%) of sustained virological response even when high baseline RAS prevalence has been reported. In the context of RAS emergence and high rates of sustained viral response, the clinical relevance of variants harboring RAS is still controversial. Therefore, in order to summarize the data available in international guidelines, we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs.
publishDate 2021
dc.date.none.fl_str_mv 2021-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/170891
Ridruejo, Ezequiel; Pereson, Matías Javier; Flichman, Diego Martin; Di Lello, Federico Alejandro; Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions; Baishideng Publishing Group; World Journal of Hepatology; 13; 9; 9-2021; 1069-1078
1948-5182
CONICET Digital
CONICET
url http://hdl.handle.net/11336/170891
identifier_str_mv Ridruejo, Ezequiel; Pereson, Matías Javier; Flichman, Diego Martin; Di Lello, Federico Alejandro; Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions; Baishideng Publishing Group; World Journal of Hepatology; 13; 9; 9-2021; 1069-1078
1948-5182
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4254/wjh.v13.i9.1069
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group
publisher.none.fl_str_mv Baishideng Publishing Group
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842270137143525376
score 13.13397

Publicaciones similares